Quince Therapeutics (QNCX) Projected to Post Quarterly Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) is projected to release its Q4 2024 earnings data after the market closes on Monday, March 24th. Analysts expect Quince Therapeutics to post earnings of ($0.19) per share for the quarter.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.09). The company had revenue of $0.17 million during the quarter. On average, analysts expect Quince Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quince Therapeutics Trading Down 2.1 %

NASDAQ:QNCX traded down $0.03 during mid-day trading on Tuesday, hitting $1.37. The company had a trading volume of 81,440 shares, compared to its average volume of 243,852. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The firm has a market cap of $60.28 million, a P/E ratio of -1.10 and a beta of 0.71. The business's fifty day moving average is $1.49 and its two-hundred day moving average is $1.44.

Analysts Set New Price Targets

QNCX has been the topic of several recent analyst reports. Oppenheimer began coverage on shares of Quince Therapeutics in a research note on Monday. They set an "outperform" rating and a $10.00 price objective on the stock. D. Boral Capital decreased their price target on shares of Quince Therapeutics from $12.00 to $4.00 and set a "buy" rating for the company in a report on Tuesday. Finally, Brookline Capital Management assumed coverage on Quince Therapeutics in a research note on Wednesday, December 18th. They set a "buy" rating and a $9.00 price objective on the stock. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Quince Therapeutics currently has an average rating of "Buy" and an average target price of $8.00.

Remove Ads

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.